-
Right-sided MCL-1 monitoring lead rhythm strip. Why might beats #4 through #7 be wide?
-
A drug has been approved to treat high plasma levels of methotrexate. Glucarpidase is a bacterial enzyme produced by recombinant DNA technology using genetically modified Exherichia coli. Glucarpidase is a carboxypeptidase enzyme that metabolizes methotrexate to its inactive metabolites. It is marketed by BTG International Inc. as Voraxaze.
-
In people without known cardiovascular disease, an increase in resting heart rate with age was associated with an increased risk of death.
-
Through a small but exquisite study, the authors of this investigatory intervention trial provide a plausible subcellular explanation for massage therapy's purported benefits on injured muscle using muscle biopsy and subsequent gene profiling. The application of similar study techniques might be expected in future studies of other CAM therapies directed against pain.
-
Evidence for the use of probiotics in a variety of medical conditions continues to accumulate.
-
The advisory committee on immunization practices (ACIP) of the CDC has updated their recommendations for immunization of health care providers (HCP) against communicable infectious diseases.
-
Between statin head-to-head trials are uncommon.
-
A meta-analysis demonstrates that earlier nephrologist referral leads to reduced mortality and hospitalization as well as better preparation and dialysis access placement.
-
Excessive daytime sleepiness appears to be an important risk factor for stroke. It is unknown whether this is related to obstructive sleep apnea or other mechanisms.
-
A new benzodiazepine anticonvulsant was recently approved for the treatment of a difficult-to-treat childhood epilepsy (Lennox-Gastaut syndrome [LGS]). Clobazam is manufactured by Catalent Pharma Solutions and marketed as ONFI.